Microbially synthesized modular virus-like particles and capsomeres displaying group A streptococcus hypervariable antigenic determinants

Biotechnology and Bioengineering

Volumn 111, Issue 6, 2014, Pages 1062-1070

  Chuan, Yap P ^a   Wibowo, Nani ^a   Connors, Natalie K ^a   Wu, Yang ^a   Hughes, Fiona K ^a   Batzloff, Michael R ^b   Lua, Linda H L ^a   Middelberg, Anton P J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

Capsomere cross reactive; Group A streptococcus; M protein; Vaccine; Virus like particle

Indexed keywords

DESIGN; DEVELOPING COUNTRIES; GASES; PEPTIDES; VACCINES; VIRUSES;

ABORIGINAL COMMUNITIES; AUSTRALIAN ABORIGINALS; CAPSOMERE CROSS-REACTIVE; GROUP A STREPTOCOCCUS; M-PROTEIN; MICROBIAL SYNTHESIS; NORTHERN TERRITORIES; VIRUS-LIKE PARTICLES;

ANTIGENS;

EPITOPE; IMMUNOGLOBULIN G ANTIBODY; M PROTEIN; PROTEIN VP1; STREPTOCOCCUS VACCINE; BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; CARRIER PROTEIN; IMMUNOGLOBULIN G; OUTER MEMBRANE PROTEIN; RECOMBINANT VACCINE; STREPTOCOCCAL M PROTEIN; SUBUNIT VACCINE; VIROSOME; VIROSOME VACCINE;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; AUSTRALIAN ABORIGINE; BACTERICIDAL ACTIVITY; CAPSOMERE; CONCENTRATION (PARAMETERS); CROSS REACTION; DEVELOPING COUNTRY; DRUG DELIVERY SYSTEM; ENZYME LINKED IMMUNOSORBENT ASSAY; GROUP A STREPTOCOCCAL INFECTION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SEQUENCE HOMOLOGY; SOLUBILITY; STREPTOCOCCUS GROUP A; VIRUS LIKE AGENT; ANIMAL; AUSTRALIA; BLOOD; GENETICS; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; OCEANIC ANCESTRY GROUP; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; CARRIER PROTEINS; CROSS REACTIONS; HUMANS; IMMUNOGLOBULIN G; MICE; NORTHERN TERRITORY; OCEANIC ANCESTRY GROUP; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS PYOGENES; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; VACCINES, VIROSOME; VIROSOMES;

EID: 84899508777     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.25172     Document Type: Article

References (31)

1. Anggraeni MR, Connors NK, Wu Y, Chuan YP, Lua LHL, Middelberg APJ. 2013. Sensitivity of immune response quality to influenza helix 190 antigen structure displayed on a modular virus-like particle. Vaccine 31(40):4428-4435.
2. Batzloff MR, Hayman WA, Davies MR, Zeng M, Pruksakorn S, Brandt ER, Good MF. 2003. Protection against group A streptococcus by immunization with J8-diphtheria toxoid: Contribution of J8-and diphtheria toxoid-specific antibodies to protection. J Infect Dis 187(10):1598-1608.
3. Bisno AL, Rubin FA, Cleary PP, Dale JB. 2005. Prospects for a group a streptococcal vaccine: Rationale, feasibility, and obstacles-Report of a national institute of allergy and infectious diseases workshop. Clin Infect Dis 41(8):1150-1156.
4. Brandt ER, Sriprakash KS, Hobb RI, Hayman WA, Zeng WG, Batzloff MR, Jackson DC, Good MF. 2000a. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian aboriginal population. Nat Med 6(4):455-459.
5. Brandt ER, Teh T, Relf WA, Hobb RI, Good MF. 2000b. Protective and nonprotective epitopes from amino termini of M proteins from Australian aboriginal isolates and reference strains of group A streptococci. Infect Immun 68(12):6587-6594.
6. Carapetis JR, Steer AC, Mulholland EK, Weber M. 2005. The global burden of group A streptococcal diseases. Lancet Infect Dis 5(11):685-694.
7. Chuan YP, Fan YY, Lua L, Middelberg APJ. 2008a. Quantitative analysis of virus-like particle size and distribution by field-flow fractionation. Biotechnol Bioeng 99(6):1425-1433.
8. Chuan YP, Lua LHL, Middelberg APJ. 2008b. High-level expression of soluble viral structural protein in Escherichia coli. J Biotechnol 134(1/2):64-71.
9. 2+-triggered switch in the thermodynamic attraction between structural protein capsomeres. J R Soc Interface 7(44):409-421.
10. Chuan YP, Rivera-Hernandez T, Wibowo N, Connors NK, Wu Y, Hughes FK, Lua LHL, Middelberg APJ. 2013. Effects of pre-existing anti-carrier immunity and antigenic element multiplicity on efficacy of a modular virus-like particle vaccine. Biotechnol Bioeng 110(9):2343-2351.
11. Dale JB, Penfound TA, Chiang EY, Walton WJ. 2011. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci. Vaccine 29(46):8175-8178.
12. Henningham A, Chiarot E, Gillen CM, Cole JN, Rohde M, Fulde M, Ramachandran V, Cork AJ, Hartas J, Magor G, Djordjevic SP, Cordwell SJ, Kobe B, Sriprakash KS, Nizet V, Chhatwal GS, Margarit IYR, Batzloff MR, Walker MJ. 2012. Conserved anchorless surface proteins as group A streptococcal vaccine candidates. J Mol Med 90(10):1197-1207.
13. Liew MWO, Rajendran A, Middelberg APJ. 2010. Microbial production of virus-like particle vaccine protein at gram-per-litre levels. J Biotechnol 150(2):224-231.
14. Liew MWO, Chuan YP, Middelberg APJ. 2012a. High-yield and scalable cell-free assembly of virus-like particles by dilution. Biochem Eng J 67:88-96.
15. Liew MWO, Chuan YP, Middelberg APJ. 2012b. Reactive diafiltration for assembly and formulation of virus-like particles. Biochem Eng J 68:120-128.
16. Lipin DI, Raj A, Lua LHL, Middelberg APJ. 2009. Affinity purification of viral protein having heterogeneous quaternary structure: Modeling the impact of soluble aggregates on chromatographic performance. J Chromatogr A 1216(30):5696-5708.
17. McNeil SA, Halperin SA, Langley JM, Smith B, Warren A, Sharratt GP, Baxendale DM, Reddish MA, Hu MC, Stroop SD, et al. 2005. Safety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 41(8):1114-1122.
18. Middelberg APJ, Rivera-Hernandez T, Wibowo N, Lua LHL, Fan Y, Magor G, Chang C, Chuan YP, Good MF, Batzloff MR. 2011. A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines. Vaccine 29(41):7154-7162.
19. Mody KT, Popat A, Mahony D, Cavallaro AS, Yu C, Mitter N. 2013. Mesoporous silica nanoparticles as antigen carriers and adjuvants for vaccine delivery. Nanoscale 5(12):5167-5179.
20. Noad R, Roy P. 2003. Virus-like particles as immunogens. Trends Microbiol 11(9):438-444.
21. Pandey M, Batzloff MR, Good MF. 2009. Mechanism of protection induced by group A streptococcus vaccine candidate J8-DT: Contribution of B and T-cells towards protection. PLoS ONE 4(4):e5147.
22. Pattenden LK, Middelberg APJ, Niebert M, Lipin DI. 2005. Towards the preparative and large-scale precision manufacture of virus-like particles. Trends Biotechnol 23(10):523-529.
23. Relf WA, Cooper J, Brandt ER, Hayman WA, Anders RF, Pruksakorn S, Currie B, Saul A, Good MF. 1996. Mapping a conserved conformational epitope from the M protein of group A streptococci. Pept Res 9(1):12-20.
24. Rivera-Hernandez T, Hartas J, Wu Y, Chuan YP, Lua LHL, Good M, Batzloff MR, Middelberg APJ. 2013. Self-adjuvanting modular virus-like particles for mucosal vaccination against group A streptococcus (GAS). Vaccine 31(15):1950-1955.
25. Shaila MS, Nayak R, Prakash SS, Georgousakis M, Brandt E, McMillan DJ, Batzloff MR, Pruksakorn S, Good MF, Sriprakash KS. 2007. Comparative in silico analysis of two vaccine candidates for group A streptococcus predicts that they both may have similar safety profiles. Vaccine 25(18):3567-3573.
26. Smeesters PR, McMillan DJ, Sriprakash KS. 2010. The streptococcal M protein: A highly versatile molecule. Trends Microbiol 18(6):275-282.
27. Spier RE. 1997. Multivalent vaccines: Prospects and challenges. Folia Microbiol 42(2):105-112.
28. Steer AC, Law I, Matatolu L, Beall BW, Carapetis JR. 2009. Global emm type distribution of group A streptococci: Systematic review and implications for vaccine development. Lancet Infect Dis 9(10):611-616.
29. Tart AH, Walker MJ, Musser JM. 2007. New understanding of the group A streptococcus pathogenesis cycle. Trends Microbiol 15(7):318-325.
30. Vallhov H, Kupferschmidt N, Gabrielsson S, Paulie S, Strømme M, Garcia-Bennett AE, Scheynius A. 2012. Adjuvant properties of mesoporous silica particles tune the development of effector T cells. Small 8(13):2116-2124.
31. Wibowo N, Chuan YP, Lua LHL, Middelberg APJ. 2013. Modular engineering of a microbially-produced viral capsomere vaccine for influenza. Chem Eng Sci 103:12-20.